Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2014

01-05-2014 | Original Article

Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes

Authors: Xinyu Xu, Shuai Zheng, Fan Yang, Yun Shi, Yong Gu, Heng Chen, Mei Zhang, Tao Yang

Published in: Endocrine | Issue 1/2014

Login to get access

Abstract

Type 1 diabetes (T1D) is perceived as an autoimmune disease caused by T cell-mediated destruction of the insulin-producing pancreatic β cells. However, the number of inflammatory T cells in blood, as well as the relative importance of each cell type is unclear. Forty-two patients with T1D and 30 controls were enrolled. Circulating primary CD4+ or CD8+ T cells were quantified with 5-color flow cytometry. Serum IL-22 and IL-17 levels were examined by ELISA. Serum autoantibodies were measured by radio-binding assays, using 35S-labeled glutamic acid decarboxylase-65 (GAD65), protein tyrosine phosphatase-2 (IA-2), and zinc transporter 8 (ZnT8). Th17–Th22 and Tc1–Tc17 were significantly elevated in patients with T1D compared to control subjects, while there were no significant differences in Th1 cells. The levels of these T cells in different stages of T1D were investigated. Th22 cells showed a positive correlation with Th17 cells in T1D patients. However, we did not find any correlation between IL-17 and IL-22 in sera. Autoantibodies were not significantly different between patients with early T1D and those who have had it for a longer duration. This study indicates that Th22 may contribute to the pathogenesis of T1D. Blockade of Th22 cells might be of clinical profit in T1D patients.
Literature
1.
J.A. Bluestone, K. Herold, G. Eisenbarth, Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464(7293), 1293–1300 (2010)CrossRefPubMed
2.
J.A. Emamaullee, J. Davis, S. Merani, C. Toso, J.F. Elliott, A. Thiesen, A.M. Shapiro, Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58(6), 1302–1311 (2009)CrossRefPubMedCentralPubMed
3.
R. Jain, D.M. Tartar, R.K. Gregg, R.D. Divekar, J.J. Bell, H.H. Lee, P. Yu, J.S. Ellis, C.M. Hoeman, C.L. Franklin, H. Zaghouani, Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 205(1), 207–218 (2008)CrossRefPubMedCentralPubMed
4.
J. Honkanen, J.K. Nieminen, R. Gao, K. Luopajarvi, H.M. Salo, J. Ilonen, M. Knip, T. Otonkoski, O. Vaarala, IL-17 immunity in human type 1 diabetes. J Immunol 185(3), 1959–1967 (2010)CrossRefPubMed
5.
P. Miossec, T. Korn, V.K. Kuchroo, Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361(9), 888–898 (2009)CrossRefPubMed
6.
S. Arif, F. Moore, K. Marks, T. Bouckenooghe, C.M. Dayan, R. Planas, M. Vives-Pi, J. Powrie, T. Tree, P. Marchetti, G.C. Huang, E.N. Gurzov, R. Pujol-Borrell, D.L. Eizirik, M. Peakman, Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 60(8), 2112–2119 (2011)CrossRefPubMedCentralPubMed
7.
M. Ryba-Stanislawowska, M. Skrzypkowska, M. Mysliwiec, J. Mysliwska, Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum. Immunol. 74(6), 701–707 (2013)CrossRefPubMed
8.
S. Trifari, C.D. Kaplan, E.H. Tran, N.K. Crellin, H. Spits, Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10(8), 864–871 (2009)CrossRefPubMed
9.
M. Veldhoen, K. Hirota, A.M. Westendorf, J. Buer, L. Dumoutier, J.C. Renauld, B. Stockinger, The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191), 106–109 (2008)CrossRefPubMed
10.
L. Zhang, Y.G. Li, Y.H. Li, L. Qi, X.G. Liu, C.Z. Yuan, N.W. Hu, D.X. Ma, Z.F. Li, Q. Yang, W. Li, J.M. Li, Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 7(4), e31000 (2012)CrossRefPubMedCentralPubMed
11.
S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, A. Blauvelt, Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130(5), 1373–1383 (2010)CrossRefPubMedCentralPubMed
12.
T. Liu, L. Peng, P. Yu, Y. Zhao, Y. Shi, X. Mao, W. Chen, P. Cheng, T. Wang, N. Chen, J. Zhang, X. Liu, N. Li, G. Guo, W. Tong, Y. Zhuang, Q. Zou, Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J. Clin. Immunol. 32(6), 1332–1339 (2012)CrossRefPubMed
13.
M.E. Truchetet, N.C. Brembilla, E. Montanari, Y. Allanore, C. Chizzolini, Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res. Ther. 13(5), R166 (2011)CrossRefPubMedCentralPubMed
14.
T. Kondo, H. Takata, F. Matsuki, M. Takiguchi, Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J. Immunol. 182(4), 1794–1798 (2009)CrossRefPubMed
15.
M. Huber, S. Heink, H. Grothe, A. Guralnik, K. Reinhard, K. Elflein, T. Hunig, H.W. Mittrucker, A. Brustle, T. Kamradt, M. Lohoff, A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 39(7), 1716–1725 (2009)CrossRefPubMed
16.
A.M. Intlekofer, A. Banerjee, N. Takemoto, S.M. Gordon, C.S. Dejong, H. Shin, C.A. Hunter, E.J. Wherry, T. Lindsten, S.L. Reiner, Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321(5887), 408–411 (2008)CrossRefPubMedCentralPubMed
17.
D.M. Kuang, C. Peng, Q. Zhao, Y. Wu, L.Y. Zhu, J. Wang, X.Y. Yin, L. Li, L. Zheng, Tumor-activated monocytes promote expansion of IL-17-producing CD8 + T cells in hepatocellular carcinoma patients. J. Immunol. 185(3), 1544–1549 (2010)CrossRefPubMed
18.
J.S. Tzartos, M.A. Friese, M.J. Craner, J. Palace, J. Newcombe, M.M. Esiri, L. Fugger, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172(1), 146–155 (2008)CrossRefPubMedCentralPubMed
19.
P.C. Res, G. Piskin, O.J. de Boer, C.M. van der Loos, P. Teeling, J.D. Bos, M.B. Teunissen, Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5(11), e14108 (2010)CrossRefPubMedCentralPubMed
20.
A. Saxena, S. Desbois, N. Carrie, M. Lawand, L.T. Mars, R.S. Liblau, Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. J. Immunol. 189(6), 3140–3149 (2012)CrossRefPubMed
21.
L. Yu, K. Herold, H. Krause-Steinrauf, P.L. McGee, B. Bundy, A. Pugliese, J. Krischer, G.S. Eisenbarth, Rituximab selectively suppresses specific islet antibodies. Diabetes 60(10), 2560–2565 (2011)CrossRefPubMedCentralPubMed
22.
T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, F. Sallusto, Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10(8), 857–863 (2009)CrossRefPubMed
23.
N. Zhang, H.F. Pan, D.Q. Ye, Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol. Cell. Biochem. 353(1–2), 41–46 (2011)CrossRefPubMed
24.
H. Chen, F. Wen, X. Zhang, S.B. Su, Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy. Molecular vision 18, 219–226 (2012)PubMedCentralPubMed
25.
X.Y. Yang, H.Y. Wang, X.Y. Zhao, L.J. Wang, Q.H. Lv, Q.Q. Wang, Th22, but not Th17 Might be a Good Index to Predict the Tissue Involvement of Systemic Lupus Erythematosus. J. Clin. Immunol. 33(4), 767–774 (2013)CrossRefPubMed
26.
S. Tsai, A. Shameli, P. Santamaria, CD8 + T cells in type 1 diabetes. Adv. Immunol. 100, 79–124 (2008)CrossRefPubMed
27.
M. Huber, S. Heink, A. Pagenstecher, K. Reinhard, J. Ritter, A. Visekruna, A. Guralnik, N. Bollig, K. Jeltsch, C. Heinemann, E. Wittmann, T. Buch, O. Prazeres da Costa, A. Brustle, D. Brenner, T.W. Mak, H.W. Mittrucker, B. Tackenberg, T. Kamradt, M. Lohoff, IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Investig. 123(1), 247–260 (2013)CrossRefPubMedCentralPubMed
28.
C. Ortega, A.S. Fernandez, J.M. Carrillo, P. Romero, I.J. Molina, J.C. Moreno, M. Santamaria, IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 86(2), 435–443 (2009)CrossRefPubMed
29.
H. Hamada, L. Garcia-Hernandez Mde, J.B. Reome, S.K. Misra, T.M. Strutt, K.K. McKinstry, A.M. Cooper, S.L. Swain, R.W. Dutton, Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182(6), 3469–3481 (2009)CrossRefPubMedCentralPubMed
30.
C.S. Hinrichs, A. Kaiser, C.M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z.A. Borman, P. Muranski, N.P. Restifo, Type 17 CD8 + T cells display enhanced antitumor immunity. Blood 114(3), 596–599 (2009)CrossRefPubMedCentralPubMed
31.
S. Eyerich, K. Eyerich, A. Cavani, C. Schmidt-Weber, IL-17 and IL-22: siblings, not twins. Trends Immunol. 31(9), 354–361 (2010)CrossRefPubMed
32.
E. Volpe, N. Servant, R. Zollinger, S.I. Bogiatzi, P. Hupe, E. Barillot, V. Soumelis, A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9(6), 650–657 (2008)CrossRefPubMed
33.
Y. Zheng, D.M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, W. Ouyang, Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128), 648–651 (2007)CrossRefPubMed
34.
F. Abbasi, P. Amiri, F.A. Sayahpour, S. Pirmoradi, M. Abolhalaj, B. Larijani, J.T. Bazzaz, M.M. Amoli, TGF-beta and IL-23 gene expression in unstimulated PBMCs of patients with diabetes. Endocrine 41(3), 430–434 (2012)CrossRefPubMed
35.
P.R. Mangan, L.E. Harrington, D.B. O’Quinn, W.S. Helms, D.C. Bullard, C.O. Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, C.T. Weaver, Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441(7090), 231–234 (2006)CrossRefPubMed
36.
M. Ryba-Stanislawowska, M. Skrzypkowska, J. Mysliwska, M. Mysliwiec, The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators Inflamm. 2013, 205284 (2013)CrossRefPubMedCentralPubMed
37.
P.J. Bingley, Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. 95(1), 25–33 (2010)CrossRefPubMed
38.
P. Achenbach, K. Koczwara, A. Knopff, H. Naserke, A.G. Ziegler, E. Bonifacio, Mature high-affinity immune responses to (pro) insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J. Clin. Invest. 114(4), 589–597 (2004)CrossRefPubMedCentralPubMed
39.
P. Vardi, A.G. Ziegler, J.H. Mathews, S. Dib, R.J. Keller, A.T. Ricker, J.I. Wolfsdorf, R.D. Herskowitz, A. Rabizadeh, G.S. Eisenbarth et al., Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diabetes Care 11(9), 736–739 (1988)PubMed
40.
S.A. Arslanian, D.J. Becker, B. Rabin, R. Atchison, M. Eberhardt, D. Cavender, J. Dorman, A.L. Drash, Correlates of insulin antibodies in newly diagnosed children with insulin-dependent diabetes before insulin therapy. Diabetes 34(9), 926–930 (1985)CrossRefPubMed
41.
J.M. Wenzlau, M. Walter, T.J. Gardner, L.M. Frisch, L. Yu, G.S. Eisenbarth, A.G. Ziegler, H.W. Davidson, J.C. Hutton, Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J. Clin. Endocrinol. Metab. 95(10), 4712–4719 (2010)CrossRefPubMedCentralPubMed
42.
P. Achenbach, E. Bonifacio, A.J. Williams, A.G. Ziegler, E.A. Gale, P.J. Bingley, Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 51(3), 488–492 (2008)CrossRefPubMed
Metadata
Title
Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes
Authors
Xinyu Xu
Shuai Zheng
Fan Yang
Yun Shi
Yong Gu
Heng Chen
Mei Zhang
Tao Yang
Publication date
01-05-2014
Publisher
Springer US
Published in
Endocrine / Issue 1/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0030-z

Other articles of this Issue 1/2014

Endocrine 1/2014 Go to the issue

Editorial

99mTc-MIBI imaging in thyroid nodules: Is it useful?

Original Article

A large deletion of the AVPR2 gene causing severe nephrogenic diabetes insipidus in a Turkish family

Original Article

Maternal nutritional history modulates the hepatic IGF–IGFBP axis in adult male rat offspring

Letter to the Editor

Panhypopituitarism in a pregnant women caused by a cystic sellar lesion

Original Article

Intranuclear cytoplasmic inclusions in cytologically suspicious or malignant thyroid nodules: identification and correlation with echogenicity and size of the nodules

Meta-Analysis

Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits